Day 1 BreakdownThe #PCG2025 Symposium commenced on an inspiring note, setting the stage for two days of insightful discussions, collaborations, and knowledge exchange.Opening SessionDr. Ratnesh Jain, Founder & Director, Mumbai Cluster, delivered the inaugural address, sharing his vision of bringing together pharma professionals, R&D experts, CXOs, and academicians to accelerate advancements in…
2023, remained a busy year for PharmaShots. To keep our readers up to date on the developments in the healthcare sector, PharmaShots worked steadfastly to deliver real-time and real-world updates. Here’s a synopsis of our key reports and most-read news of the year. Top 20 Radiopharma Companies Based on Market Cap Shots: Integrating scintigraphy with…
Shots: Matthew G. Fishler, Chief Engineer and Director of Product Development Abbott’s Cardiac Rythm Management Business, in an insightful conversation with PharmaShots Matthew shares the highlights of the recently approved AVEIR Dr, the world’s first dual-chamber leadless pacemaker system for patients with slower-than-normal or abnormal heart rhythms Equipped with i2i™ communication technology, AVIER DR eliminates…
In a recent interview with PharmaShots, Kai te Kaat, the Vice President, Head of Franchise Oncology, MDx at QIAGEN shares his insights and highlights on QIAprep& Viral RNA UM Kit.Shots:QIAGEN to launch the QIAprep& Viral RNA UM Kit, designed to simplify and accelerate PCR swab analysis and remove key testing bottlenecks for Covid-19 and other RNA virusesThe…
1. Pfizer Launched its Zirabev (biosimilar, bevacizumab) in the US by the year end 2019Date - Oct 01, 2019Product - Zirabev (biosimilar, bevacizumab)The biosimilar was launched in the US on Dec 31, 2019 following the settlement between Genentech and Pfizer granting all global rights of the product to the Pfizer. In Sept 2019,…
The third quarter of 2019 has ended with major acquisitions in the pharma and biotech industry along with multiple approvals. Starting with the latest acquisition where Biocon Biologics acquires Pfizer's Research Facility for expansion of its R&D footprints with the acceleration of the development of its biosimilars from lab to pilot scale. Previously, Amgen acquired…
The second quarter of 2019 has ended with major acquisitions in pharma and biotech industry. Moving with the latest acquisition of Allergan for $63B by AbbVie focusing on to generate revenue with addition of Allergan's medical aesthetics and ophthalmology portfolio. Prior to that, Pfizer acquired Array Biopharma for $11.4B to expand its oncology portfolio. Some…

